Natco Pharma acquires 40 million shares in eGenesis Inc for USD 8 million

The Hyderabad-headquartered drugmaker, in a statement, said the eGenesis Genome Engineering and Production platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.

eGenesis is advancing development programs for kidney transplants, acute liver failure and heart transplants, it said.

“We are excited to get involved with eGenesis, Inc. with respect to their pioneering work in xenotransplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transform the treatment of organ failure by eliminating waitlist mortality,” Rajeev Nannapaneni, Vice Chairman and CEO of Natco, said.

“We are thrilled to welcome Natco as an investor. Their support will be used in advancing our research and bringing our innovative therapies to market,” said Mike Curtis, CEO of eGenesis Inc.

In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorised by the U.S. Food and Drug Administration (FDA) under the Expanded Access pathway.